Stockholm3 abstract wins 1st prize at European Association of Urology
July 14, 2021
An abstract presenting the STHLM3 MR trial was awarded the “1st Prize Best Abstract Oncology 2021” at the annual European Association of Urology meeting. The trial included 12,750 men and concluded that combining the Stockholm3 test with MRI for prostate cancer screening decreases overdetection by 69 percent compared to Standard of Care, while maintaining detection of significant cancer.
In total, 4,000 abstracts were presented at the annual European Association of Urology, the largest scientific meeting in Europe within the field of Urology. The abstract “Risk-adapted screening with genomics and MRI: STHLM3 MR Phase 2 Trial” presented by Dr Tobias Nordström, Karolinska Institutet was awarded 1st Prize Best Abstract Oncology 2021.
The STHLM3 MR Trial is a randomized screen-by-invitation trial, comparing the standard test PSA with the Stockholm3 blood test when used with MRI-targeted or systematic biopsies for prostate cancer detection.
12,750 men in the age between 50 and 74 years participated in the trial. Compared to a screening strategy using PSA and systematic biopsies, Stockholm3 combined with MRI-targeted biopsies was associated with 69 percent fewer low-grade cancers and 53 percent fewer biopsy procedures.
“The results that Dr Nordström presented at EAU, in combination with our recently published paper in New England Journal of Medicine, provide evidence that the Stockholm3 test in combination with MRI provides a powerful and safe tool for prostate cancer screening. The significant reduction of overdetection and unnecessary procedures justifies introduction of general screening in men between the age of 50 and 74 to reduce their risk of dying of prostate cancer,” said Dr Henrik Grönberg, co-founder of A3P Biomedical and Professor of cancer epidemiology at Karolinska Institutet.
“These pivotal study results add to the significant body of data from studies of in total 80,000 men providing evidence of the value the Stockholm3 test. The healthcare providers in the Nordics that already transitioned to Stockholm3 are delivering outstanding results; 100 percent more aggressive cancers found, 50 percent reduction of unnecessary biopsies and 17 to 28 percent lower costs. A3P Biomedical is committed to making the Stockholm3 test available worldwide and look forward to work with our partners to improve men’s health and quality of life”, said David Rosen, CEO at A3P Biomedical.
About A3P Biomedical
A3P Biomedical is a company that specializes in advanced prostate cancer diagnostics. A3P’s main product, Stockholm3, is a clinically and commercially validated blood test for early detection and risk stratification of aggressive prostate cancer. A3P Biomedical is headquartered in Stockholm, Sweden. For more information, please visit www.a3p.com
About Stockholm3
Stockholm3 is a blood-based test, that runs a combination of protein biomarkers, genetic biomarkers and clinical information through an algorithm to find the probability of clinically significant cancer at biopsy.
Stockholm3 has been evaluated in clinical studies including more than 90,000 men. It is extensively tested in large population-based screening trials, as well as in real world clinical utility studies in primary care, as a reflex test to PSA at values 1.5-20 ng/ml. Benefits include the ability to reduce unnecessary MRIs, benign and Grade Group 1 prostate biopsies for men with elevated PSA, while simultaneously improving detection of clinically significant cancers in men with low or normal PSA values. Using Stockholm3 leads to a more accurate risk assessment than the current PSA standard. Stockholm3 detects 40-90% more men with aggressive prostate cancer and, at the same time, reduces over-detection by 40-50% compared to PSA.
Multiple Stockholm3 studies have been published in high-impact journals such as The Lancet Oncology, Journal of Clinical Oncology, and European Urology. The studies address both the specificity and sensitivity of Stockholm3 in multi-ethnic populations as well as health-economic benefits of implementing it in clinical care. For more information about our clinical studies please visit www.a3p.com.
About prostate cancer
Prostate cancer is the most common cancer in men. In 2020, the global incidence of new prostate cancer cases was 1.4 million, and prostate cancer specific mortality 370,000. Global prostate cancer incidence and mortality is expected to rise by 100% and 85% respectively by 2040, driven by an ageing population.
Press contact:
Cecilia Edström
cecilia.edstrom@a3p.com
+46 72 226 2328